Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 上海微创电生理医疗科技股份有限公司（ShanghaiMicroPortEPMedTechCo.,Ltd.）（以下简称“微创电生理”）于2010年8月31日在上海国际医学园区设立。微创电生理是一家专注于电生理介入诊疗与消融治疗领域创新医疗器械研发、生产和销售的高新技术企业，致力于提供具备全球竞争力的“以精准介入导航为核心的诊断及消融治疗一体化解决方案”。为满足快速性心律失常患者的治疗需求，公司自成立以来始终坚持核心技术的创新与突破，经过十余年的持续创新，公司完成了全面涵盖心脏电生理手术的产品布局，是首个能够提供三维心脏电生理设备与耗材完整解决方案的国产厂商，并实现了“射频+冷冻”两大主流消融能量产品的协同布局。2022年8月31日，公司于上海证券交易所科创板上市（688351.SH）。
Main Business 电生理介入诊疗与消融治疗领域创新医疗器械研发、生产和销售。
Legal Representative YIYONG SUN（孙毅勇)
Top Executives
董事长：顾哲毅
董事：蒋磊,刘荻,张国旺,YIYONG SUN(孙毅勇)
独立董事：杨健,栾依峥,宋成利
Top 5 Shareholder
Shareholder name Nature Holding Date
宁波梅山保税港区铧杰股权投资管理有限公司－嘉兴华杰一号股权投资合伙企业（有限合伙）限售股34.94%30/09/2024
微创投资控股有限公司限售股32.71%30/09/2024
上海生晖企业管理咨询中心（有限合伙）限售股3.22%30/09/2024
上海毓衡投资管理中心（有限合伙）流通A股2.96%30/09/2024
天津爱德博瑞企业管理合伙企业（有限合伙）限售股2.59%30/09/2024
Company Secretary 朱郁
Solicitors 北京世辉律师事务所
Auditors 大华会计师事务所（特殊普通合伙）
Tel No 021-60969600
Fax No 021-20903925
Website www.everpace.com
Email investors@everpace.com
Company Address
Register: 上海市浦东新区周浦镇天雄路588弄1-28号第28幢
Office: 上海市浦东新区周浦镇天雄路588弄1-28号第28幢
Listing Date 31/08/2022
Shares Capital
Shares Capital: 470,600,000
Total A Share: 470,600,000
Listed A Share: 124,859,881
Non-tradable A Share: 345,740,119
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.012
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 3.581
Market Capitalization(RMB) 2.670B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.